[go: up one dir, main page]

EP1996937A4 - Genetic packages and uses thereof - Google Patents

Genetic packages and uses thereof

Info

Publication number
EP1996937A4
EP1996937A4 EP07752549A EP07752549A EP1996937A4 EP 1996937 A4 EP1996937 A4 EP 1996937A4 EP 07752549 A EP07752549 A EP 07752549A EP 07752549 A EP07752549 A EP 07752549A EP 1996937 A4 EP1996937 A4 EP 1996937A4
Authority
EP
European Patent Office
Prior art keywords
genetic packages
packages
genetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07752549A
Other languages
German (de)
French (fr)
Other versions
EP1996937A2 (en
Inventor
Volker Schellenberger
Willem P Stemmer
Chia-Wei Wang
Michael D Scholle
Mikhail Popkov
Nathaniel C Gordon
Andreas Crameri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1996937(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/528,950 external-priority patent/US20070212703A1/en
Application filed by Amunix Inc filed Critical Amunix Inc
Publication of EP1996937A2 publication Critical patent/EP1996937A2/en
Publication of EP1996937A4 publication Critical patent/EP1996937A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07752549A 2006-03-06 2007-03-06 Genetic packages and uses thereof Withdrawn EP1996937A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74341006P 2006-03-06 2006-03-06
US74362206P 2006-03-21 2006-03-21
US11/528,950 US20070212703A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
US11/528,927 US20070191272A1 (en) 2005-09-27 2006-09-27 Proteinaceous pharmaceuticals and uses thereof
PCT/US2007/005857 WO2007103455A2 (en) 2006-03-06 2007-03-06 Genetic packages and uses thereof

Publications (2)

Publication Number Publication Date
EP1996937A2 EP1996937A2 (en) 2008-12-03
EP1996937A4 true EP1996937A4 (en) 2009-04-08

Family

ID=38475542

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20140189047 Ceased EP2863222A1 (en) 2006-03-06 2007-03-06 Unstructured recombinant polymers and uses thereof
EP07752636.6A Active EP1996220B2 (en) 2005-09-27 2007-03-06 Unstructured recombinant polymers and uses thereof
EP07752549A Withdrawn EP1996937A4 (en) 2006-03-06 2007-03-06 Genetic packages and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP20140189047 Ceased EP2863222A1 (en) 2006-03-06 2007-03-06 Unstructured recombinant polymers and uses thereof
EP07752636.6A Active EP1996220B2 (en) 2005-09-27 2007-03-06 Unstructured recombinant polymers and uses thereof

Country Status (6)

Country Link
EP (3) EP2863222A1 (en)
AU (2) AU2007223855B2 (en)
CA (1) CA2644712C (en)
DK (1) DK2402754T4 (en)
SI (1) SI2402754T2 (en)
WO (2) WO2007103515A2 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516056C (en) 2003-01-06 2012-05-29 Angiochem Inc. Aprotinin and analogs as carriers across the blood-brain barrier
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009525946A (en) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
SI2173890T1 (en) 2007-06-21 2011-06-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
CN103298935A (en) * 2007-08-15 2013-09-11 阿穆尼克斯公司 Compositions and methods for improving the performance of biologically active polypeptides
CN105727261A (en) 2008-06-27 2016-07-06 杜克大学 Therapeutic agents comprising elastic peptides
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
MX2011005963A (en) 2008-12-05 2011-09-01 Angiochem Inc Conjugates of neurotensin or neurotensin analogs and uses thereof.
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2015218510B2 (en) * 2009-02-03 2016-11-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
CA2748314C (en) * 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
MX2011013183A (en) * 2009-06-08 2012-04-20 Amunix Operating Inc POLYPEPTIDES OF THE HORMONE OF GROWTH AND METHODS OF PREPARATION AND ITS USE.
JP5839597B2 (en) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド Glucose-regulating polypeptide and methods for making and using the same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
IN2012DN00248A (en) * 2009-07-02 2015-05-01 Angiochem Inc
WO2011028228A1 (en) * 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
CN102164949B (en) * 2009-11-19 2013-10-23 浙江大学 Novel recombinant fusion protein
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP4450523A3 (en) * 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
TWI510246B (en) 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
CA2794614C (en) 2010-05-21 2020-12-15 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
JP5709985B2 (en) 2010-06-18 2015-04-30 シーバーサイエンス ゲーエムベーハー Peptides as active agents that stabilize biological barriers
MY192639A (en) 2010-07-09 2022-08-29 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
CN113278077A (en) 2010-11-26 2021-08-20 分子组合公司 Designed repeat proteins that bind to serum albumin
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
KR102110736B1 (en) 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN104271150A (en) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP2819788B1 (en) 2012-02-27 2018-08-22 Amunix Operating Inc. Xten conjugate compositions and methods of making same
PL2846836T3 (en) 2012-05-07 2020-01-31 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
CA3062003C (en) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
PT2882450T (en) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
TWI750197B (en) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Methods of using fix polypeptides
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP3065761B1 (en) 2013-11-05 2020-01-08 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
EP4176894B1 (en) 2014-01-10 2024-02-28 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
JP6652932B2 (en) 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン synTac polypeptides and uses thereof
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
NZ735803A (en) 2015-04-02 2021-12-24 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
US11208452B2 (en) 2015-06-02 2021-12-28 Novo Nordisk A/S Insulins with polar recombinant extensions
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
KR20180038560A (en) 2015-08-28 2018-04-16 아뮤닉스 오퍼레이팅 인코포레이티드 Chimeric polypeptide assemblies and methods for their manufacture and use
MA43348A (en) 2015-10-01 2018-08-08 Novo Nordisk As PROTEIN CONJUGATES
KR20190044029A (en) 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. Variant PD-L1 polypeptides, T-cell modulated multimeric polypeptides and methods for their use
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7250677B2 (en) 2016-12-22 2023-04-03 キュー バイオファーマ， インコーポレイテッド T cell regulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
SG11201908391XA (en) 2017-03-15 2019-10-30 Cue Biopharma Inc Methods for modulating an immune response
MA49339A (en) 2017-04-05 2020-02-12 Novo Nordisk As Oligomer extended insulin-fc conjugates
AU2018327224A1 (en) 2017-09-07 2020-04-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
CN111886241A (en) 2018-01-09 2020-11-03 库尔生物制药有限公司 Multimeric T cell modulating polypeptides and methods of use thereof
WO2019201855A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Lysosomal fusion protein
MX2020012397A (en) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Methods of treating hemophilia a.
TWI856047B (en) 2018-12-19 2024-09-21 美商信號生物製藥公司 Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020181062A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2020180501A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory antigen-presenting polypeptides and methods of use thereof
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
JP2023545684A (en) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド Polypeptide conjugates and methods of use
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
EP4259199A1 (en) 2020-12-11 2023-10-18 Friedrich Miescher Institute for Biomedical Research Hdac6 binding proteins and their anti-viral use
CN115083016A (en) * 2022-06-09 2022-09-20 广州紫为云科技有限公司 Monocular camera-based small-target-oriented hand space interaction method and device
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD257197A1 (en) † 1987-01-28 1988-06-08 Univ Dresden Tech METHOD FOR THE PRODUCTION OF IMMOBILIZED INSULIN PRAEPARATIONS STABILIZED IN ITS BIOLOGICAL ACTIVITY AND MODIFIED IN ITS PHARMACOLOGICAL PROPERTIES
FR2647677B1 (en) * 1989-05-31 1991-09-27 Roussel Uclaf NOVEL MICRO-PROTEINS, PROCESS FOR THE PREPARATION AND APPLICATION AS MEDICAMENTS OF SUCH NEW MICRO-PROTEINS
RU2114119C1 (en) † 1990-12-13 1998-06-27 Дзе Апджон Компани Fused protein and a method of isolation of the fused protein
US5833911A (en) † 1995-05-31 1998-11-10 Johnson & Johnson Medical, Inc. Method for forming a glove using a folded glove form
WO1998022577A1 (en) † 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
US20050260605A1 (en) * 1998-02-11 2005-11-24 Maxygen, Inc. Targeting of genetic vaccine vectors
EP1054973A1 (en) * 1998-02-11 2000-11-29 Maxygen, Inc. Antigen library immunization
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
PE20020908A1 (en) † 2001-03-21 2002-10-26 Cell Therapeutics Inc RECOMBINANT PRODUCTION OF POLYANIONIC POLYMERS AND USE OF THE SAME
KR101608083B1 (en) * 2005-01-25 2016-04-01 씨티아이 바이오파마 코포레이션 Conjugates of biologically active proteins having a modified in vivo half-life
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
JP2009525946A (en) † 2005-12-20 2009-07-16 デューク・ユニヴァーシティ Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2008049711A1 (en) † 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BULAJ GRZEGORZ ET AL: "Efficient oxidative folding of conotoxins and the radiation of venomous cone snails.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. Supplement 2, 25 November 2003 (2003-11-25), pages 14562 - 14568, XP002515375, ISSN: 0027-8424 *
CHEN X J ET AL: "Site-directed mutations in a highly conserved region of Bacillus thuringiensis delta-endotoxin affect inhibition of short circuit current across Bombyx mori midguts.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 1 OCT 1993, vol. 90, no. 19, 1 October 1993 (1993-10-01), pages 9041 - 9045, XP002515378, ISSN: 0027-8424 *
GOMEZ-DUARTE O G ET AL: "Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 16, 1 November 1995 (1995-11-01), pages 1596 - 1602, XP004057422, ISSN: 0264-410X *
PI C ET AL: "Analysis of expressed sequence tags from the venom ducts of Conus striatus: focusing on the expression profile of conotoxins", BIOCHIMIE, MASSON, PARIS, FR, vol. 88, no. 2, 1 February 2006 (2006-02-01), pages 131 - 140, XP025066514, ISSN: 0300-9084, [retrieved on 20060201] *

Also Published As

Publication number Publication date
AU2007223888A1 (en) 2007-09-13
AU2007223855A1 (en) 2007-09-13
EP2863222A1 (en) 2015-04-22
EP1996937A2 (en) 2008-12-03
EP1996220B1 (en) 2013-05-08
WO2007103455A2 (en) 2007-09-13
EP1996220B2 (en) 2023-08-16
CA2644712C (en) 2016-09-13
SI2402754T2 (en) 2023-09-29
CA2644712A1 (en) 2007-09-13
DK2402754T3 (en) 2015-01-12
DK2402754T4 (en) 2023-08-28
AU2007223855B2 (en) 2013-05-16
WO2007103515A3 (en) 2008-04-03
WO2007103455A3 (en) 2007-11-29
WO2007103515A2 (en) 2007-09-13
EP1996220A4 (en) 2009-04-29
EP1996220A2 (en) 2008-12-03
SI2402754T1 (en) 2015-02-27

Similar Documents

Publication Publication Date Title
EP1996937A4 (en) Genetic packages and uses thereof
ZA200810323B (en) Fkbp-l and uses thereof
LT2064327T (en) Dbait and uses thereof
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA200902823B (en) Oligoribonucleotides and uses thereof
IL196397A0 (en) Prlr-specific antibody and uses thereof
AU313874S (en) Package
IL194751A0 (en) Drugs and uses
GB0621160D0 (en) Compounds and uses thereof
ZA200903906B (en) Carboranylporphyrins and uses thereof
IL196861A0 (en) Antibodies against ccr5 and uses thereof
IL195525A0 (en) Replikin peptides and uses thereof
IL193469A0 (en) Novel lipases and uses thereof
EP2124908A4 (en) Compounds and uses thereof
GB0604187D0 (en) Peptide and uses thereof
EP2120563A4 (en) Compounds and uses thereof
EP2099459A4 (en) Compounds and uses thereof
GB0603717D0 (en) Electricity-generate and store
PL2032708T3 (en) Recombinant novirhabdoviruses and uses thereof
IL192800A0 (en) Fgf2-binding peptides and uses thereof
EP2120957A4 (en) Compounds and uses thereof
ZA200807233B (en) Novel lipases and uses thereof
GB0621665D0 (en) Blogmail and podmail
GB2444960B (en) Combined pseudoscope and hyperscope
GB0615557D0 (en) Compounds and Uses Thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081006

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20090305

17Q First examination report despatched

Effective date: 20090717

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMUNIX OPERATING INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110421